Neuroprotective Mechanisms of ARA-290: Promoting Nerve Repair and Reducing Inflammation

by Dr. James Ross

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Nerves and Temperature: Understanding Their Connection

Although the idea was proposed long ago, it is now better understood that nerve receptor endings contain unspecialized branches that respond to temperature changes. Recent advances have revealed the molecular mechanisms underlying thermoreception. Ion channels, including those within all neurons, are influenced by temperature because their gating processes are temperature-sensitive. However, only certain neurons act as dedicated thermoreceptors, and just a few ion channel types qualify as true thermosensors.

Thermoreceptors detect changes in temperature rather than fixed values, largely because they adapt quickly.

How Temperature Sensitivity Arises at the Molecular Level

Several explanations have been suggested for how temperature influences TRP channels:

• Heat may generate a ligand that activates the receptor.
• Temperature shifts could alter the structure of the channel, triggering it to open.
• Heat may change membrane structure or tension, which in turn modifies channel activity.

For example, because capsaicin produces a burning sensation, it has been proposed that heat and capsaicin use similar mechanisms to activate TRPV1, designating it as a genuine heat sensor.

Roles of TRP and TREK Channels in Thermal Sensing

Evidence indicates that TRP and TREK channels are key to two major thermal processes:

1. Detecting thermal sensations at the peripheral level, functioning as thermosensors in neurons and skin cells.
2. Helping regulate overall body temperature, particularly through neurons in the hypothalamus.

TREK channels are mostly inactive at room temperature but become strongly responsive when stimulated. TRP channels, however, respond differently: some are activated by heat, while others are activated by cold. Both systems collaborate with other thermosensitive proteins like Na/K ATPase, ENaC channels, and P2X receptors.

Comparing TRP and TREK Channel Functions

Important differences exist between these two groups:

1. TREK channels are potassium channels with negative reversal potentials, reducing thermoreceptor excitability upon activation. TRPs, as cationic channels, increase excitability when activated.
2. TREKs open more with increasing heat, while TRPs can respond to either rising or falling temperatures. Together, both families work in a complementary manner to produce sensations of heat, cold, and thermal pain.

Blocking TRPV1 as a Target Against Drug-Induced Reward

Research shows that blocking TRPV1 receptors can reduce morphine tolerance, prevent drug-seeking behaviors (cocaine, methamphetamine), and limit methamphetamine-induced increases in TRPV1 expression. This highlights TRPV1 as a target in drug reward pathways.

ARA-290 as a TRPV1 Inhibitor

ARA-290 exerts pain-relieving effects through anti-inflammatory and immune-regulating activity, primarily by engaging the innate repair receptor (IRR). Studies demonstrate that ARA-290 also directly inhibits TRPV1 activity in sensory neurons, reducing capsaicin-induced hypersensitivity.

ARA-290 Preserves Vascular Integrity After Burns

In untreated wounds, the vascular area decreases rapidly after injury. ARA-290 treatment, however, preserved and expanded the vascular area significantly within 48 hours, preventing blood supply loss at wound sites.

ARA-290 Reduces Inflammation by Lowering Adhesion Molecules

ARA-290 suppressed TNF-α and IL-1β–driven endothelial adhesion molecules, reducing leukocyte adhesion and vascular injury. In wound sites, ARA-290 altered TNF-α dynamics, preventing the early damaging spike observed in untreated groups.

Clinical Trial: ARA-290 Improves Neuropathic Pain and Well-Being

In patients with type 2 diabetes, ARA-290 improved neuropathic pain scores significantly compared to placebo. Benefits were most notable for tingling, thermal pain, and allodynia, and improvements persisted beyond treatment.

ARA-290 Improves Lipid and Blood Sugar Profiles

ARA-290 therapy reduced cholesterol ratios, increased HDL, and lowered triglycerides. HbA1c levels improved and remained better even weeks after treatment stopped.

ARA-290 Enhances Insulin Function in Diabetes

In diabetic rodent models, ARA-290 reduced blood glucose, improved insulin secretion, and lowered HbA1c without affecting hematocrit. It enhanced beta-cell metabolism, ATP production, and glucose-induced insulin release.

ARA-290: An EPO Derivative With Protective Benefits Without Blood Risks

Unlike erythropoietin (EPO), which can cause blood thickening, ARA-290 is a short peptide derivative that activates the same protective pathways without hematopoietic effects. Clinical trials show improvements in HbA1c and neuropathy symptoms.

Kidney Protection and Anti-Fibrotic Effects of ARA-290

In kidney injury studies, ARA-290 improved filtration rates, lowered fibrosis, and reduced inflammatory signals. It also enhanced endothelial function without cardiovascular side effects.

ARA-290’s Healing Effects Depend on the IRR Pathway

ARA-290 activates IRR, a receptor complex that modulates neuroinflammation and promotes repair. In animal and human studies, ARA-290 improved neuropathic symptoms, promoted nerve fiber regrowth, and reduced allodynia.

ARA-290 Reduces Neuropathy in Sarcoidosis

In sarcoidosis patients with neuropathy, ARA-290 reduced pain and promoted small nerve fiber regrowth in the cornea. Similar benefits were observed in type 2 diabetes patients. Both groups showed improved metabolic health with no significant side effects.

ARA-290 Protects Against Neuroinflammation

By targeting inflammatory pathways (TNF-α, NF-κB, cytokines), ARA-290 decreases neuroinflammation after nerve injury. It crosses the blood–brain barrier, offering neuroprotection in stroke, spinal cord injury, and diabetic models.

ARA-290 and Immune Regulation via T-Cell Control

ARA-290, like EPO, reduces T-cell proliferation and alters Th1/Th2/Th17 differentiation. This shifts the immune response toward anti-inflammatory pathways, supporting recovery from autoimmune neuropathies.

ARA-290 Supports Myelin Repair and Lowers Nerve Inflammation

In neuritis models, ARA-290 reduced demyelination, promoted remyelination, and decreased inflammatory infiltration in nerve tissues.

ARA-290 Boosts Healing While Reducing Cytokines

ARA-290 enhanced macrophage ability to clear debris while lowering pro-inflammatory cytokines, contributing to tissue repair and recovery in neuropathies and lupus.

ARA-290 Enhances Cellular Stress Response to Misfolded Proteins

By enhancing stress response pathways, ARA-290 promoted protein refolding, reduced toxic aggregates, and potentially protected against neurodegenerative diseases such as Alzheimer’s and Parkinson’s.

ARA-290 Ameliorates Lupus Through Immune Regulation

In lupus models, ARA-290 lowered autoantibodies, reduced kidney inflammation, and improved immune regulation without increasing red blood cell production.

ARA-290 Limits Splenic Inflammation and Enlargement

ARA-290 decreased immune cell infiltration in lymph nodes and spleen, mitigating splenomegaly and inflammation in autoimmune disease models.

ARA-290 Shields Cells From Ischemic Damage

ARA-290 prevented muscle cell death and inflammation under conditions of reduced blood supply, showing potential for use in critical limb ischemia.

ARA-290 Supports Longevity and Heart Function

In aging studies, ARA-290 preserved heart rate, ejection fraction, and reduced frailty, suggesting benefits for healthy lifespan extension.

ARA-290 Enhances Calcium Mobilization in Pancreatic Islets

ARA-290 enhanced calcium signaling in pancreatic islets, improving insulin secretion and supporting glucose regulation.

REFERENCES

1. Bohr S, Patel SJ, Shen K, Vitalo AG, Brines M, Cerami A, Berthiaume F, Yarmush ML. Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3513-8. doi: 10.1073/pnas.1214099110. Epub 2013 Feb 11. PMID: 23401545; PMCID: PMC3587271.
2. Dahan A, Brines M, Niesters M, Cerami A, van Velzen M. Targeting the innate repair receptor to treat neuropathy. Pain Rep. 2016 Aug 9;1(1):e566. doi: 10.1097/PR9.0000000000000566. PMID: 29392190; PMCID: PMC5741312.
3. Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015 Mar 13;20(1):658-66. doi: 10.2119/molmed.2014.00215. PMID: 25387363; PMCID: PMC4365069.
4. Liu Y, Luo B, Han F, Li X, Xiong J, Jiang M, Yang X, Wu Y, Zhang Z. Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection. PLoS One. 2014 Mar 6;9(3):e90942. doi: 10.1371/journal.pone.0090942. Erratum in: PLoS One. 2014;9(5):e99555. Dosage error in article text. PMID: 24603865; PMCID: PMC3946253.
5. Zhang W, Yu G, Zhang M. ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception. Peptides. 2016 Feb;76:73-9. doi: 10.1016/j.peptides.2016.01.003. Epub 2016 Jan 13. PMID: 26774587.
6. Tian YH, Ma SX, Lee KW, Wee S, Koob GF, Lee SY, Jang CG. Blockade of TRPV1 Inhibits Methamphetamine-induced Rewarding Effects. Sci Rep. 2018 Jan 17;8(1):882. doi: 10.1038/s41598-018-19207-2. PMID: 29343767; PMCID: PMC5772440.
7. Chen H, Luo B, Yang X, Xiong J, Liu Z, Jiang M, Shi R, Yan C, Wu Y, Zhang Z. Therapeutic effects of nonerythropoietic erythropoietin analog ARA290 in experimental autoimmune encephalomyelitis rat. J Neuroimmunol. 2014 Mar 15;268(1-2):64-70. doi: 10.1016/j.jneuroim.2014.01.006. Epub 2014 Jan 28. PMID: 24518674.
8. Joshi D, Abraham D, Shiwen X, Baker D, Tsui J. Potential role of erythropoietin receptors and ligands in attenuating apoptosis and inflammation in critical limb ischemia. J Vasc Surg. 2014 Jul;60(1):191-201, 201.e1-2. doi: 10.1016/j.jvs.2013.06.054. Epub 2013 Sep 20. PMID: 24055514.